U C Inc.

Equities

SMMR

US87155J1088

Delayed OTC Markets Other stock markets 03:15:22 2024-04-29 pm EDT			5-day change	1st Jan Change
0.00794 ^USD	-29.98%		-.--%	-60.50%

2022	U C, Inc. Appoints Michael Coner as Member of the Board of Directors, Secretary of the Company, and its Chief Operating Officer	CI
2022	U C, Inc. Appoints David Reckles as CEO	CI

Symmetry Technologies Inc. Moves to Lab Test and Develop its Inducible Expression System for Biosynthetic Production of Testerone in Men

October 07, 2013 at 08:00 am EDT

Symmetry Technologies Inc. announced that it has initiated contact with a US based BioScience research and testing facility in its efforts to further develop the company's Inducible Expression System for Biosynthetic Production of Testosterone in Men.

Latest news about U C Inc.

U C, Inc. Appoints Michael Coner as Member of the Board of Directors, Secretary of the Company, and its Chief Operating Officer	22-02-23	CI
U C, Inc. Appoints David Reckles as CEO	22-02-21	CI
U C, Inc. Appoints David Reckles as New Board Member	22-02-21	CI
Symmetry Technologies Inc. has Changed its Name to U C, Inc	21-12-02	CI
Symmetry Announces Security Complete PlusGRC for ERP Environments	16-07-12	CI
Symmetry Technologies Inc. Moves to Lab Test and Develop its Inducible Expression System for Biosynthetic Production of Testerone in Men	13-10-07	CI

Chart U C Inc.

Duration

Period

More charts

Company Profile

Sector

More about the company